How did ICCM's Q4 earnings surprise impact annual performance?

IceCure Medical Ltd. (ICCM) experienced a quarterly loss of $0.08 per share for Q3, which was a surprise of -14.29% as it missed the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.

1. **Impact on Annual Performance**:
- **Earnings Impact**: The Q3 loss of $0.08 per share would naturally have a significant impact on the annual earnings per share calculation if the company were to simply sum up the quarterly losses. However, since ICCM has only reported three quarters, we do not have the annual figure to directly calculate the impact. But, the Q3 loss would depress the annual EPS figure if the company were to use a simple quarterly sum.
- **Revenue Impact**: ICCM posted revenues of $0.66 million for Q3, which is a 102% increase from the same period last year, but it missed the Zacks Consensus Estimate by 5.43%. This suggests that while the company is showing revenue growth, it is still below market expectations. For the annual revenue calculation, this would be a positive contribution, but again, the exact impact would depend on the total annual revenue figure, which is not provided.
- **Stock Performance and Future Outlook**: The sustainability of ICCM's stock performance will largely depend on management's commentary on the earnings call. The company's shares have underperformed the market so far this year, which could influence investor sentiment and future earnings expectations.

In conclusion, ICCM's Q3 earnings surprise of a larger-than-expected loss would likely have a negative impact on the company's annual earnings per share, but the actual annual figures are not available. The revenue miss could also affect the annual revenue figure, but again, the full-year context is missing from the reported data. The company's stock performance and future outlook will be key factors for investors to watch.